Nello Mainolfi exercised and sold 50,000 shares at $119.00 under a pre-scheduled trading plan, retaining $79.5 million in equity.
Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6.0 million on July 7, 2026, after exercising stock options at a $2.08 strike price. The shares were sold at a weighted average price of $119.00, reflecting a 3.70% premium over the prior day’s close of $114.76.
The transaction followed a 170% total return over the past 12 months and was executed under a Rule 10b5-1 trading plan adopted on March 24, 2026. Mainolfi retains 666,568 shares, valued at $79.5 million, along with 90,000 stock options.
Kymera Therapeutics, a biopharmaceutical company, focuses on small molecule therapeutics using targeted protein degradation.